Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results

被引：0

作者：

Papp, Kim A. ^{[1
]}

Menter, Martin A. ^{[2
]}

Abe, Masatoshi ^{[3
]}

Elewski, Boni E. ^{[4
]}

Feldman, Steven R. ^{[5
]}

Gottlieb, Alice G. ^{[6
]}

Thaci, Diamant ^{[7
]}

Luger, Thomas ^{[8
]}

Tatulych, Svitlana ^{[9
]}

Gupta, Pankaj ^{[9
]}

Proulx, James ^{[9
]}

Lan, Shu-Ping ^{[9
]}

Wolk, Robert ^{[9
]}

机构：

[1] Probity Med Res & K Papp Clin Res Inc, Waterloo, ON, Canada

[2] Baylor Res Inst, Dallas, TX USA

[3] Gunma Univ Hosp, Maebashi, Japan

[4] Univ Alabama, Tuscaloosa, AL 35487 USA

[5] Wake Forest Univ, Winston Salem, NC 27109 USA

[6] Tufts Med Ctr, Boston, MA USA

[7] Univ Hosp Schleswig Holstein, Kiel, Germany

[8] Univ Munster, Dept Dermatol, D-48149 Munster, Germany

[9] Pfizer Inc, Groton, CT 06340 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2015年 / 72卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

2020

引用

页码：AB66 / AB66

页数：1

共 50 条

[1] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
Blauvelt, Andrew
Papp, Kim A.
Gooderham, Melinda
Langley, Richard G.
Leonardi, Craig
Lacour, Jean-Philippe
Philipp, Sandra
Tyring, Stephen
Bukhalo, Michael
Wu, Jashin J.
Bagel, Jerry
Frankel, Ellen H.
Pariser, David
Flack, Mary
Scherer, Joseph
Geng, Ziqian
Gu, Yihua
Camez, Anne
Thompson, Elizabeth H. Z.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
[2] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
Kaur, M.
Merola, J.
Tatulych, S.
Mamolo, C.
Lan, S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
[3] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Kaur, Mandeep
Lan, Shuping
Mallbris, Lotus
Mamolo, Carla
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
[4] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Mamolo, Carla
Lan, Shuping
Mallbris, Lotus
Kaur, Mandeep
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[5] Efficacy and safety of risankizumab, an Il-23 inihibitor in patients with moderate-to-severe chronic Plaque Psoriasis: 16-week Phase 3 IMMhance Trial results
Blauvelt, A.
Papp, K.
Gooderham, M.
Langley, R. G.
Leonardi, C.
Lacour, J. P.
Philipp, S.
Tyring, S.
Bukhalo, M.
Wu, J. J.
Bagel, J.
Frankel, E. H.
Pariser, D.
Flack, M.
Scherer, J.
Geng, Z.
Gu, Y.
Camez, A.
Thompson, E. H. Z.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 18 - 18
[6] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
Merola, Joseph F.
Elewski, Boni
Tatulych, Svitlana
Lan, Shuping
Tallman, Anna
Kaur, Mandeep
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 79 - +
[7] Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
Fiorillo, Loretta
Becker, Emily
de Lucas, Raul
Belloni-Fortina, Anna
Armesto, Susana
Elewski, Boni
Maes, Peter
Oberoi, Rajneet K.
Paris, Maria
Zhang, Wendy
Zhang, Zuoshun
Arkin, Lisa
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1232 - 1239
[8] Efficacy and safety of oral tofacitinib in North American patients with moderate to severe plaque psoriasis: Pooled analyses of data from randomized phase 3 studies
Korman, Neil J.
King, Brett
Wolk, Robert
Tan, Huaming
Kaur, Mandeep
Robertson, Debbie
Langley, Richard
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
[9] Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
Umezawa, Yoshinori
Sakurai, Shinya
Hoshii, Naoki
Nakagawa, Hidemi
DERMATOLOGY AND THERAPY, 2021, 11 (02) : 513 - 528
[10] Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
Yoshinori Umezawa
Shinya Sakurai
Naoki Hoshii
Hidemi Nakagawa
Dermatology and Therapy, 2021, 11 : 513 - 528

← 1 2 3 4 5 →